Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 COST ANALYSIS BREAKDOWN
8 TECHNONLOGY ROADMAP
9 INNOVATION TRACKER AND STRATEGIC ANALYSIS
9.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
9.1.1 JOINT VENTURES
9.1.2 MERGERS AND ACQUISITIONS
9.1.3 LICENSING AND PARTNERSHIP
9.1.4 TECHNOLOGY COLLABORATIONS
9.1.5 STRATEGIC DIVESTMENTS
9.2 NUMBER OF PRODUCTS IN DEVELOPMENT
9.3 STAGE OF DEVELOPMENT
9.4 TIMELINES AND MILESTONES
9.5 INNOVATION STRATEGIES AND METHODOLOGIES
9.6 RISK ASSESSMENT AND MITIGATION
9.7 FUTURE OUTLOOK
10 REGULATORY COMPLIANCE
10.1 REGULATORY AUTHORITIES
10.2 REGULATORY CLASSIFICATIONS
10.2.1 CLASS I
10.2.2 CLASS II
10.2.3 CLASS III
10.3 REGULATORY SUBMISSIONS
10.4 INTERNATIONAL HARMONIZATION
10.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
10.6 REGULATORY CHALLENGES AND STRATEGIES
11 REIMBURSEMENT FRAMEWORK
12 VALUE CHAIN ANALYSIS
13 HEALTHCARE ECONOMY
13.1 HEALTHCARE EXPENDITURE
13.2 CAPITAL EXPENDITURE
13.3 CAPEX TRENDS
13.4 CAPEX ALLOCATION
13.5 FUNDING SOURCES
13.6 INDUSTRY BENCHMARKS
13.7 GDP RATION IN OVERALL GDP
13.8 HEALTHCARE SYSTEM STRUCTURE
13.9 GOVERNMENT POLICIES
13.1 ECONOMIC DEVELOPMENT
14 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, BY PRODUCT AND SERVICES
14.1 OVERVIEW
14.2 DETECTION KITS & REAGENTS
14.2.1 LAL TEST REAGENTS
14.2.2 MYCOPLASMA DETECTION & REMOVAL
14.2.3 PCR MYCOPLASMA DETECTION KIT
14.2.4 MYCOPLASMA ELIMINATION COCKTAIL
14.2.5 OTHERS
14.3 INSTRUMENTS & SYSTEMS
14.3.1 SERIES TUBE READER
14.3.2 MICROPLATE READER
14.3.3 LOW ENDOTOXIN RECOVERY (LER)
14.3.4 ENDOTOXIN REMOVAL
14.3.5 LOW ENDOTOXIN RECOVERY (LER)
14.3.6 OTHERS
14.4 CONSUMABLES & ACCESSORIES
14.5 SOFTWARE AND SERVICES
14.6 OTHERS
15 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, BY TEST TYPE
15.1 OVERVIEW
15.2 LIMULUS AMOEBOCYTE LYSATE (LAL) TEST
15.3 MONOCYTE ACTIVATION TEST (MAT) TEST
15.4 RECOMBINANT FACTOR C (RFC) ASSAY
15.5 RABBIT PYROGEN TEST
16 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, BY TYPE
16.1 OVERVIEW
16.2 PRE-FORMED ENDOTOXIN AND PYROGEN TESTING
16.3 PROENDOTOXIN AND PYROGEN TESTING
16.4 COMBINE ENDOTOXIN AND PYROGEN TESTING
17 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, BY FORM
17.1 OVERVIEW
17.2 POWDER
17.3 LIQUID
18 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, BY PRODUCT CATEGORY
18.1 OVERVIEW
18.2 CLEAN LABELED INGREDIENT
18.3 CONVENTIONAL
19 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, BY APPLICATION
19.1 OVERVIEW
19.2 PHARMACEUTICAL MANUFACTURING
19.3 MEDICAL DEVICE MANUFACTURING
19.4 RAW MATERIALS PRODUCTION
19.5 PACKAGING MANUFACTURE
20 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, BY METHOD
20.1 OVERVIEW
20.2 GEL CLOT ENDOTOXIN AND PYROGEN TEST
20.3 CHROMOGENIC ENDOTOXIN AND PYROGEN TEST
20.4 TURBIDIMETRIC ENDOTOXIN AND PYROGEN TEST
21 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, BY MODE OF PURCHASE
21.1 OVERVIEW
21.2 LARGE GROUP
21.3 MID AND SMALL GROUP
21.4 INDIVIDUAL
22 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, BY END PRODUCT
22.1 OVERVIEW
22.2 BIOLOGICS
22.3 VACCINES AND/ OR CGT
22.4 INJECTABLES
22.5 OTHERS
22.5.1 ENDOSCOPES
22.5.2 REUSABLE BIOMEDICAL DEVICES
22.5.3 OTHERS
23 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, BY END USER
23.1 OVERVIEW
23.2 PHARMACEUTICAL COMPANIES
23.3 BIOTECHNOLOGY COMPANIES
23.4 BIOMEDICAL COMPANIES
23.5 MEDICAL DEVICE COMPANIES
23.6 CONTRACT RESEARCH ORGANIZATION (CRO)
23.7 CONTRACT MANUFACTURING ORGANIZATION (CMO)
24 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, GEOGRAPHY
24.1 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.2 NORTH AMERICA
24.2.1 U.S.
24.2.2 CANADA
24.2.3 MEXICO
24.3 EUROPE
24.3.1 GERMANY
24.3.2 FRANCE
24.3.3 U.K.
24.3.4 ITALY
24.3.5 SPAIN
24.3.6 RUSSIA
24.3.7 BELGIUM
24.3.8 NETHERLANDS
24.3.9 SWITZERLAND
24.3.10 REST OF EUROPE
24.4 ASIA-PACIFIC
24.4.1 JAPAN
24.4.2 CHINA
24.4.3 SOUTH KOREA
24.4.4 INDIA
24.4.5 AUSTRALIA
24.4.6 SINGAPORE
24.4.7 MALAYSIA
24.4.8 REST OF ASIA-PACIFIC
24.5 SOUTH AMERICA
24.5.1 BRAZIL
24.5.2 ARGENTINA
24.5.3 REST OF SOUTH AMERICA
24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA PACIFIC
25.5 MERGERS & ACQUISITIONS
25.6 NEW PRODUCT DEVELOPMENT & APPROVALS
25.7 EXPANSIONS
25.8 REGULATORY CHANGES
25.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, SWOT AND DBMR ANALYSIS
27 GLOBAL ENDOTOXIN AND PYROGEN TESTING MARKET, COMPANY PROFILE
27.1 PALL EUROPE LIMITED (DANAHER CORPORATION)
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 THERMO FISHER SCIENTIFIC INC.
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 CHARLES RIVER LABORATORIES
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 EUROFINS SCIENTIFIC
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 PACIFIC BIOLABS
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 LONZA
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 MERCK KGAA
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 STERIS
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 SARTORIUS AG
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 BIOMÉRIEUX
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 FUJIFILM WAKO PURE CHEMICAL CORPORATION
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 ELLAB A/S.
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 ASSOCIATES OF CAPE COD, INC (SEIKAGAKU CORPORATION)
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 WUXI APPTEC
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
27.16 GENSCRIPT
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPMENTS
27.17 MICROCOAT BIOTECHNOLOGIE GMBH
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPMENTS
27.18 SANQUIN
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPMENTS
27.19 READING SCIENTIFIC SERVICES LTD
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPMENTS
27.2 NANOCOMPOSIX
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPMENTS
27.21 ZWISLER LABORATORIUM GMBH
27.21.1 COMPANY OVERVIEW
27.21.2 REVENUE ANALYSIS
27.21.3 GEOGRAPHIC PRESENCE
27.21.4 PRODUCT PORTFOLIO
27.21.5 RECENT DEVELOPMENTS
27.22 NELSON LABORATORIES, LLC – A SOTERA HEALTH COMPANY
27.22.1 COMPANY OVERVIEW
27.22.2 REVENUE ANALYSIS
27.22.3 GEOGRAPHIC PRESENCE
27.22.4 PRODUCT PORTFOLIO
27.22.5 RECENT DEVELOPMENTS
27.23 NORTH AMERICAN SCIENCE ASSOCIATES, LLC
27.23.1 COMPANY OVERVIEW
27.23.2 REVENUE ANALYSIS
27.23.3 GEOGRAPHIC PRESENCE
27.23.4 PRODUCT PORTFOLIO
27.23.5 RECENT DEVELOPMENTS
27.24 PROMEGA CORPORATION
27.24.1 COMPANY OVERVIEW
27.24.2 REVENUE ANALYSIS
27.24.3 GEOGRAPHIC PRESENCE
27.24.4 PRODUCT PORTFOLIO
27.24.5 RECENT DEVELOPMENTS
27.25 HYCULT BIOTECH INC.
27.25.1 COMPANY OVERVIEW
27.25.2 REVENUE ANALYSIS
27.25.3 GEOGRAPHIC PRESENCE
27.25.4 PRODUCT PORTFOLIO
27.25.5 RECENT DEVELOPMENTS
27.26 ALMAC GROUP
27.26.1 COMPANY OVERVIEW
27.26.2 REVENUE ANALYSIS
27.26.3 GEOGRAPHIC PRESENCE
27.26.4 PRODUCT PORTFOLIO
27.26.5 RECENT DEVELOPMENTS
27.27 MAT BIOTECH
27.27.1 COMPANY OVERVIEW
27.27.2 REVENUE ANALYSIS
27.27.3 GEOGRAPHIC PRESENCE
27.27.4 PRODUCT PORTFOLIO
27.27.5 RECENT DEVELOPMENTS
27.28 SOLVIAS
27.28.1 COMPANY OVERVIEW
27.28.2 REVENUE ANALYSIS
27.28.3 GEOGRAPHIC PRESENCE
27.28.4 PRODUCT PORTFOLIO
27.28.5 RECENT DEVELOPMENTS
27.29 WICKHAM MICRO LIMITED
27.29.1 COMPANY OVERVIEW
27.29.2 REVENUE ANALYSIS
27.29.3 GEOGRAPHIC PRESENCE
27.29.4 PRODUCT PORTFOLIO
27.29.5 RECENT DEVELOPMENTS
27.3 CREATIVE BIOLABS
27.30.1 COMPANY OVERVIEW
27.30.2 REVENUE ANALYSIS
27.30.3 GEOGRAPHIC PRESENCE
27.30.4 PRODUCT PORTFOLIO
27.30.5 RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
28 RELATED REPORTS
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
